New Hampshire Becomes Latest State to Propose CBD Regs to Fill FDA Vacuum

New Hampshire Becomes Latest State to Propose CBD Regs to Fill FDA Vacuum

NPA’s Kyle Turk Testifies in Public Hearing

WASHINGTON – As the Food and Drug Administration (FDA) continues to defy mounting requests from the US Congress and the natural products industry to provide science-based and public health regulations for CBD, more states are rushing in to fill the vacuum.  New Hampshire recently became the latest state to propose new state regulations for consumable hemp and CBD products.

Kyle Turk, Director for Government Affairs, for the Natural Products Association will testify in a public hearing before the Environment and Agriculture Committee on January 27, 2021 at 1:00 PM EST in support of HB 272.  NPA’s testimony can be viewed here.

“The states continue to demonstrate that it is possible to take action on CBD products while managing the COVID-19 health crisis,” said Kyle Turk, Director of Government Relations for NPA.  “The pandemic is not an excuse for the FDA to skirt its responsibilities to protect public health in other areas.  We applaud the states for taking action to regulate CBD, and we will continue to lead the conversations guiding states to establish a regulatory pathway for CBD. Over the last two years, NPA has worked with policymakers across the country, including in New Jersey, Utah, Rhode Island and Georgia, to establish a regulatory framework for CBD products. No other organization has had a greater impact shaping CBD policy at the state level than NPA.”

NPA has been the leader in asking the FDA to regulate CBD since 2017, has testified on a number of occasions, and has held several meetings with top FDA officials on the issue.  NPA also helped craft legislation passed by the U.S. House of Representatives that provides resources so the FDA can perform a Health Hazard Evaluation (HHE) and set a safe level of CBD for consumers to use each day.  The process would follow the same precedent as red yeast rice, which allows a natural product to contain a level of a drug ingredient that the FDA has determined to be safe. With the exception of Epidiolexall CBD products in the U.S. are considered illegal by the federal government.